

ONE HUNDRED EIGHTH LEGISLATURE - SECOND SESSION - 2024
COMMITTEE STATEMENT
LB1126

Hearing Date: Wednesday February 14, 2024
Committee On: Judiciary
Introducer: Bosn
One Liner: Create the National Career Readiness Certificate Pilot Program within the Department of Correctional Services

Roll Call Vote - Final Committee Action:
Advanced to General File with amendment(s)

Vote Results:
Aye: 7 Senators Blood, Bosn, DeBoer, DeKay, Holdcroft, Ibach, Wayne
Nay:
Absent:
Present Not Voting: 1 Senator McKinney

Testimony:

Proponents:

Senator Carolyn Bosn
Mary LeFebvre
Amy Doty
Jasmine Harris
Diane Good-Collins
Jason Witmer

Representing:

Opening Presenter
ACT
Southeast Community College
RISE
Metropolitan Community College
American Civil Liberties Union of Nebraska

Opponents:

Representing:

Neutral:

Representing:

* ADA Accommodation Written Testimony

Summary of purpose and/or changes:

LB1126 creates the National Career Readiness Certificate Pilot Program ("the Program") which will assist justice-involved individuals with obtaining the National Career Readiness Certificate. This certificate is a credential that substantiates key skills across various industries and roles. The Program is administered by the Department of Correctional Services ("DCS").

LB1126 requires DCS to annually evaluate the success of the Program and report to the Clerk of the Legislature.

LB1126 also states an intent to appropriate \$500,000 to DCS from the general fund for fiscal years 2024-2025 and 2025-2026 to carry out the Program.



Explanation of amendments:

AM3261 adds the entirety of LB892 as amended by Judiciary Committee AM2765.

LB892 amends Section 28-405 to update the list of controlled substances to include metonitazene, eutylone, mesocarb, methiopropamine, and xylazine. This section also removes fenfluramine. LB892 also amends Section 28-416 to make a harmonizing change. The committee amendment, AM2765, replaces the addition of xylazine to list specific chemical designations of xylazine and exclude the administration of xylazine to animals.

AM3261 also adds the entirety of LB795.

Currently, Section 28-470 provides immunity for the administration of naloxone under certain circumstances. LB795 amends Section 28-470 to replace each use of the word “naloxone” with the term “opioid antagonist,” which is defined to include naloxone and any other FDA-approved method of reversing an opioid overdose.

Justin Wayne, Chairperson

